Channelpedia

PubMed 18070091


Referenced in Channelpedia wiki pages of: none

Automatically associated channels: HCN1 , Nav1.1 , Nav1.6



Title: Early treatment suppresses the development of spike-wave epilepsy in a rat model.

Authors: Hal Blumenfeld, Joshua P Klein, Ulrich Schridde, Matthew Vestal, Timothy Rice, Davender S Khera, Chhitij Bashyal, Kathryn Giblin, Crystal Paul-Laughinghouse, Frederick Wang, Anuradha Phadke, John Mission, Ravi K Agarwal, Dario J Englot, Joshua Motelow, Hrachya Nersesyan, Stephen G Waxman, April R Levin

Journal, date & volume: Epilepsia, 2008 Mar , 49, 400-9

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/18070091


Abstract
Current treatments for epilepsy may control seizures, but have no known effects on the underlying disease. We sought to determine whether early treatment in a model of genetic epilepsy would reduce the severity of the epilepsy phenotype in adulthood.We used Wistar albino Glaxo rats of Rijswijk (WAG/Rij) rats, an established model of human absence epilepsy. Oral ethosuximide was given from age p21 to 5 months, covering the usual period in which seizures develop in this model (age approximately 3 months). Two experiments were performed: (1) cortical expression of ion channels Nav1.1, Nav1.6, and HCN1 (previously shown to be dysregulated in WAG/Rij) measured by immunocytochemistry in adult treated rats; and (2) electroencephalogram (EEG) recordings to measure seizure severity at serial time points after stopping the treatment.Early treatment with ethosuximide blocked changes in the expression of ion channels Nav1.1, Nav1.6, and HCN1 normally associated with epilepsy in this model. In addition, the treatment led to a persistent suppression of seizures, even after therapy was discontinued. Thus, animals treated with ethosuximide from age p21 to 5 months still had a marked suppression of seizures at age 8 months.These findings suggest that early treatment during development may provide a new strategy for preventing epilepsy in susceptible individuals. If confirmed with other drugs and epilepsy paradigms, the availability of a model in which epileptogenesis can be controlled has important implications both for future basic studies, and human therapeutic trials.